T. Rowe Price Investment Management’s Vaxcyte PCVX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $195M | Buy |
6,001,124
+3,298,433
| +122% | +$107M | 0.12% | 181 |
|
|
2025
Q1 | $102M | Sell |
2,702,691
-158,026
| -6% | -$5.97M | 0.07% | 276 |
|
|
2024
Q4 | $234M | Sell |
2,860,717
-1,193,111
| -29% | -$97.7M | 0.14% | 158 |
|
|
2024
Q3 | $463M | Buy |
4,053,828
+31,239
| +0.8% | +$3.57M | 0.28% | 95 |
|
|
2024
Q2 | $304M | Buy |
4,022,589
+469,622
| +13% | +$35.5M | 0.19% | 129 |
|
|
2024
Q1 | $243M | Buy |
3,552,967
+2,306,926
| +185% | +$158M | 0.15% | 163 |
|
|
2023
Q4 | $78.3M | Buy |
1,246,041
+41,413
| +3% | +$2.6M | 0.05% | 316 |
|
|
2023
Q3 | $61.4M | Buy |
1,204,628
+61,710
| +5% | +$3.15M | 0.04% | 338 |
|
|
2023
Q2 | $57.1M | Buy |
1,142,918
+409,011
| +56% | +$20.4M | 0.04% | 360 |
|
|
2023
Q1 | $27.5M | Buy |
733,907
+222,471
| +43% | +$8.34M | 0.02% | 438 |
|
|
2022
Q4 | $24.5M | Buy |
+511,436
| New | +$24.5M | 0.02% | 438 |
|